Earnings ·
Smith & Nephew reported first-half revenue of $3,097 million and trading profit of $566 million for the period ending…
SNNSmith & Nephew PLC
Smith & Nephew reported first-half revenue of $3,097 million and trading profit of $566 million for the period ending June 27, 2026. The company revised its full-year underlying revenue growth guidance down from approximately 6% to around 4%, citing softer performance in US Orthopaedics and Advanced Wound Bioactives. Despite the revenue adjustment, trading profit, free cash flow, and return on invested capital guidance remain unchanged at approximately $1.3 billion, $800 million, and over 10%, respectively. The firm announced a $500 million share buyback program in May, with $216 million settled as of August 3, 2026. Additionally, the interim dividend was increased by 4.0% to 15.6 cents per share. Smith & Nephew operates in the medical technology industry, manufacturing orthopaedic implants, sports medicine products, and advanced wound management solutions.